医药行业商业贿赂的治理研究
发布时间：2018-09-12 10:22
【摘要】：在社会主义市场经济体制不够完善的条件下,医药行业市场经济秩序混乱,造成以商业贿赂为代表的各种不正当竞争行为持续蔓延。商业贿赂直接影响了医疗服务水平与卫生事业发展,事关老百姓的切身利益,日益成为全民热议的焦点话题。要从根本上治理医药行业商业贿赂,就要对现行的治理措施进行反思,找出问题,通过借鉴一些国际治理经验,提出适合中国的医药行业商业贿赂治理方式。 医药行业商业贿赂的治理进程可以分为事前、事中、事后三个阶段,每个阶段存在着不同的问题。事前阶段医疗服务体制不合理,医药市场机制不畅,相关法律法规缺失；事中阶段政府的指导工作不到位,工商行政执法部门职能缺位；事后阶段司法部门重视程度不足,处罚力度过轻,标准不一。其原因主要包括,政府财政投入不足、现行法律法规效力不理想、市场准入把关不严、药品集中招标采购不规范、收入分配制度不合理、公众重视程度不足六个方面。通过构建治理长效机制来防治医药行业商业贿赂行为,具体分为制度、法律、教育并重的预防机制,医药产业发展的调控机制,医药行业监督制约机制,以及以政府为主导的多元化治理体系。
[Abstract]:Under the condition that the socialist market economy system is not perfect, the order of the medicine market economy is in disorder, resulting in various unfair competition behaviors represented by commercial bribery continue to spread. Commercial bribery has directly affected the level of medical service and the development of health care, which concerns the vital interests of the common people, and has increasingly become a hot topic of discussion among the whole people. In order to deal with the commercial bribery in medicine industry fundamentally, we should reflect on the existing measures, find out the problems, and put forward the management mode of commercial bribery suitable for China through drawing lessons from some international governance experiences. The governance process of commercial bribery in pharmaceutical industry can be divided into three stages: beforehand, during, and afterwards, each stage has its own problems. In advance, the medical service system is unreasonable, the medical market mechanism is not smooth, the relevant laws and regulations are missing; the guiding work of the government is not in place and the functions of the administrative law enforcement departments for industry and commerce are not in place at the middle stage of the incident; the judicial departments pay less attention to it after the event. The punishment was too light and varied in standard. The main reasons include inadequate government financial investment, imperfect effectiveness of current laws and regulations, inadequate market access control, non-standard centralized bidding and procurement of drugs, unreasonable income distribution system, and insufficient public attention in six aspects. To prevent and control commercial bribery in the pharmaceutical industry through the construction of a long-term mechanism of governance, it can be divided into two parts: prevention mechanism with equal emphasis on system, law and education, regulation and control mechanism for the development of pharmaceutical industry, supervision and restriction mechanism of pharmaceutical industry. And the government-led pluralistic governance system.
【学位授予单位】：天津师范大学
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：D922.294
本文编号：2238710
[Abstract]:Under the condition that the socialist market economy system is not perfect, the order of the medicine market economy is in disorder, resulting in various unfair competition behaviors represented by commercial bribery continue to spread. Commercial bribery has directly affected the level of medical service and the development of health care, which concerns the vital interests of the common people, and has increasingly become a hot topic of discussion among the whole people. In order to deal with the commercial bribery in medicine industry fundamentally, we should reflect on the existing measures, find out the problems, and put forward the management mode of commercial bribery suitable for China through drawing lessons from some international governance experiences. The governance process of commercial bribery in pharmaceutical industry can be divided into three stages: beforehand, during, and afterwards, each stage has its own problems. In advance, the medical service system is unreasonable, the medical market mechanism is not smooth, the relevant laws and regulations are missing; the guiding work of the government is not in place and the functions of the administrative law enforcement departments for industry and commerce are not in place at the middle stage of the incident; the judicial departments pay less attention to it after the event. The punishment was too light and varied in standard. The main reasons include inadequate government financial investment, imperfect effectiveness of current laws and regulations, inadequate market access control, non-standard centralized bidding and procurement of drugs, unreasonable income distribution system, and insufficient public attention in six aspects. To prevent and control commercial bribery in the pharmaceutical industry through the construction of a long-term mechanism of governance, it can be divided into two parts: prevention mechanism with equal emphasis on system, law and education, regulation and control mechanism for the development of pharmaceutical industry, supervision and restriction mechanism of pharmaceutical industry. And the government-led pluralistic governance system.
【学位授予单位】：天津师范大学
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：D922.294
【参考文献】
相关期刊论文 前10条
1 严波;;治理商业贿赂与构建公共行政伦理体系[J];中国城市经济;2011年12期
2 曾卫龙;李妮亚;朱艳华;李凌燕;潘强;;在防治医药商业贿赂中医院过度用药对策研究[J];当代医学;2009年32期
3 张丽琴;;浅析医药行业商业贿赂腐败现象及治理对策[J];法制与经济(下旬刊);2009年02期
4 钱勇涛;;医药商业贿赂成因及对策[J];法制与社会;2010年24期
5 储成鹏;;试论我国药品商业贿赂法律规制[J];法制与社会;2011年15期
6 徐向业;;略谈商业贿赂犯罪的危害和打击对策[J];法制与社会;2011年30期
7 柏岩;;论医药购销领域商业贿赂的现状与对策[J];辽宁公安司法管理干部学院学报;2009年04期
8 徐玉立;;当代医院商业贿赂发生原因与治理措施之探讨[J];中国社会医学杂志;2012年03期
9 董书平;;治理医药卫生领域商业贿赂的对策研究[J];医院管理论坛;2013年10期
10 李建华;田赞;田晖;;在华跨国商业贿赂的根源与治理对策研究——葛兰素史克案反思[J];东南学术;2014年02期
，本文编号：2238710
本文链接：https://www.wllwen.com/falvlunwen/jingjifalunwen/2238710.html
